BAF Complex Antibody Sampler Kit #12854
Product Information
Kit Usage Information
Protocols
- 3508: Western Blotting, Immunofluorescence
- 7074: Western Blotting
- 11956: Western Blotting, Immunoprecipitation (Agarose), ChIP Magnetic, Chromatin IP-seq, CUT&RUN Assay, CUT&Tag
- 11966: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence*, ChIP Magnetic
- 12354: Western Blotting, Immunohistochemistry (Paraffin), ChIP Magnetic
- 12760: Western Blotting, Immunoprecipitation (Magnetic), ChIP Magnetic, Chromatin IP-seq, CUT&RUN Assay
- 91735: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), ChIP Magnetic, Chromatin IP-seq, CUT&RUN Assay
Product Description
Specificity / Sensitivity
Each antibody in this kit recognizes endogenous levels of total protein for the specified target and does not cross-react with other family members. ARID1A/BAF250A (D2A8U) Rabbit mAb also cross-reacts with proteins of unknown origin at 65 kDa.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly1293 of human ARID1A/BAF250A protein, Gly264 of human BRM protein, Gly975 of human SMARCC1/BAF155 protein, Ile818 of human SMARCC2/BAF170 protein, or Leu120 of human SMARCB1/BAF47 protein. Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala52 of human Brg1 protein. Polyclonal antibodies are purified by Protein A and peptide affinity chromatography.
Background
ATP-dependent chromatin remodeling complexes play an essential role in the regulation of various nuclear processes, such as gene expression, DNA replication, and repair (1,2). The SWI/SNF chromatin remodeling complex consists of more than 10 subunits with a single molecule of the ATPase catalytic subunit BRM or BRG1, but not both. The activities of these two subunits drive the disruption of histone-DNA contacts that lead to changes in accessibility of crucial regulatory elements within chromatin (2-5). The BRM/BRG1 containing SWI/SNF complexes are recruited to target promoters by transcription factors, such as nuclear receptors, p53, RB, and BRCA1 to regulate gene activation, cell growth, the cell cycle, and differentiation processes (1,6-9). BRM and BRG1 are also considered to be tumor suppressors and their expression levels are severely reduced in several cancer cell lines (10-13). SMARCC1/BAF155, SMARCC2/BAF170, and SMARCB1/BAF47 are members of the core subunits of the SWI/SNF complex, which is necessary for efficient nucleosome remodeling by BRG1 in vitro (14). ARID1A/BAF250A is one of the accessory subunits of the SWI/SNF complex (15). SMARCC1, SMARCB1, and ARID1A are an essential part of the mouse embryonic stem cell specific SWI/SNF complex (esBAF). SMARCC1 is necessary for early embryogenesis, especially proper brain and visceral endoderm development (16-18). SMARCB1 is necessary for early embryogenesis and hepatocyte differentiation (19,20). ARID1A is critical for ES cell pluripotency and differentiation into mesoderm-derived cardiomyocytes and adipocytes (15). While SMARCC2 has been shown to be part of the SWI/SNF complex in non-pluripotent cells, it is absent in pluripotent embryonic stem (ES) cells. Expression of SMARCC2 has been shown to be up-regulated in neurons/neuronal progenitors upon differentiation of mouse ES cells with retinoic acid, and exogenous expression of SMARCC2 leads to loss of stem cell pluripotency and self renewal (21).
- Ho, L. and Crabtree, G.R. (2010) Nature 463, 474-84.
- Becker, P.B. and Hörz, W. (2002) Annu Rev Biochem 71, 247-73.
- Eberharter, A. and Becker, P.B. (2004) J Cell Sci 117, 3707-11.
- Bowman, G.D. (2010) Curr Opin Struct Biol 20, 73-81.
- Gangaraju, V.K. and Bartholomew, B. (2007) Mutat Res 618, 3-17.
- Lessard, J.A. and Crabtree, G.R. (2010) Annu Rev Cell Dev Biol 26, 503-32.
- Morettini, S. et al. (2008) Front Biosci 13, 5522-32.
- Wolf, I.M. et al. (2008) J Cell Biochem 104, 1580-6.
- Simone, C. (2006) J Cell Physiol 207, 309-14.
- Yamamichi, N. et al. (2005) Oncogene 24, 5471-81.
- Reisman, D.N. et al. (2002) Oncogene 21, 1196-207.
- Shen, H. et al. (2008) Cancer Res 68, 10154-62.
- Weissman, B. and Knudsen, K.E. (2009) Cancer Res 69, 8223-30.
- Phelan, M.L. et al. (1999) Mol Cell 3, 247-53.
- Gao, X. et al. (2008) Proc Natl Acad Sci U S A 105, 6656-61.
- Han, D. et al. (2008) Dev Biol 315, 136-46.
- Kim, J.K. et al. (2001) Mol Cell Biol 21, 7787-95.
- Schaniel, C. et al. (2009) Stem Cells 27, 2979-91.
- Klochendler-Yeivin, A. et al. (2000) EMBO Rep 1, 500-6.
- Gresh, L. et al. (2005) EMBO J 24, 3313-24.
- Ho, L. et al. (2009) Proc Natl Acad Sci U S A 106, 5181-6.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.